US 12,247,070 B2
Use of anti-FAM19A5 antibodies for treating atherosclerosis
Bongcheol Kim, Seongnam-si (KR); Dong Sik Kim, Seoul (KR); Jae-Keun Lee, Seoul (KR); and Juwon Shim, Seoul (KR)
Assigned to NEURACLE SCIENCE CO., LTD., Seoul (KR)
Appl. No. 17/418,681
Filed by NEURACLE SCIENCE CO., LTD., Seoul (KR)
PCT Filed Dec. 26, 2019, PCT No. PCT/IB2019/061377
§ 371(c)(1), (2) Date Jun. 25, 2021,
PCT Pub. No. WO2020/136603, PCT Pub. Date Jul. 2, 2020.
Claims priority of provisional application 62/785,569, filed on Dec. 27, 2018.
Prior Publication US 2022/0064277 A1, Mar. 3, 2022
Int. Cl. C07K 16/24 (2006.01); A61P 9/10 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/24 (2013.01) [A61P 9/10 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01)] 20 Claims
 
1. A method of increasing a migration and/or accumulation of macrophages at an atherosclerotic lesion site in a subject in need thereof comprising administering to the subject an antagonist against a family with sequence similarity 19, member A5 (“FAM19A5”) protein (“FAM19A5 antagonist”),
wherein the FAM19A5 antagonist comprises an antibody, or an antigen-binding portion thereof, that specifically binds to the FAM19A5 protein (“anti-FAM19A5 antibody”), a polynucleotide encoding the anti-FAM19A5 antibody, a vector comprising the polynucleotide, or a combination thereof,
wherein the anti-FAM19A5 antibody comprises a heavy chain CDR1, CDR2, and CDR3, and a light chain CDR1, CDR2, and CDR3, wherein:
(i) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 11, SEQ ID NO: 14, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 89, SEQ ID NO: 95, SEQ ID NO: 101, SEQ ID NO: 107, SEQ ID NO: 113, SEQ ID NO: 119, SEQ ID NO: 125, SEQ ID NO: 131, SEQ ID NO: 137, SEQ ID NO: 143, SEQ ID NO: 149, SEQ ID NO: 218, SEQ ID NO: 220, SEQ ID NO: 222, or SEQ ID NO: 223;
(ii) the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 21, SEQ ID NO: 90, SEQ ID NO: 96, SEQ ID NO: 102, SEQ ID NO: 108, SEQ ID NO: 114, SEQ ID NO: 120, SEQ ID NO: 126, SEQ ID NO: 132, SEQ ID NO: 138, SEQ ID NO: 144, SEQ ID NO: 150, SEQ ID NO: 219, SEQ ID NO: 221, SEQ ID NO: 252, or SEQ ID NO: 253;
(iii) the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 13, SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO: 22, SEQ ID NO: 91, SEQ ID NO: 97, SEQ ID NO: 103, SEQ ID NO: 109, SEQ ID NO: 115, SEQ ID NO: 121, SEQ ID NO: 127, SEQ ID NO: 133, SEQ ID NO: 139, SEQ ID NO: 145, SEQ ID NO: 151, SEQ ID NO: 246, or SEQ ID NO: 247;
(iv) the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 92, SEQ ID NO: 98, SEQ ID NO: 104, SEQ ID NO: 110, SEQ ID NO: 116, SEQ ID NO: 122, SEQ ID NO: 134, SEQ ID NO: 140, SEQ ID NO: 146, SEQ ID NO: 152, SEQ ID NO: 208, SEQ ID NO: 225, or SEQ ID NO: 248;
(v) the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 33, SEQ ID NO: 93, SEQ ID NO: 99, SEQ ID NO: 105, SEQ ID NO: 111, SEQ ID NO: 117, SEQ ID NO: 123, SEQ ID NO: 129, SEQ ID NO: 135, SEQ ID NO: 141, SEQ ID NO: 147, SEQ ID NO: 153, SEQ ID NO: 209, SEQ ID NO: 213, SEQ ID NO: 224, SEQ ID NO: 226, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, or SEQ ID NO: 232; and
(vi) the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 25, SEQ ID NO: 28, SEQ ID NO: 31, SEQ ID NO: 34, SEQ ID NO: 94, SEQ ID NO: 100, SEQ ID NO: 106, SEQ ID NO: 112, SEQ ID NO: 118, SEQ ID NO: 124, SEQ ID NO: 130, SEQ ID NO: 136, SEQ ID NO: 142, SEQ ID NO: 148, SEQ ID NO: 154, SEQ ID NO: 227, SEQ ID NO: 231, or SEQ ID NO: 233.